ArticleArchivos de cardiologia de Mexico2022
Cardiorenal syndrome: classification, pathophysiology, diagnosis and management. Literature review
Article in Archivos de cardiologia de Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05927285 (Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1
Who cites it
13 citing papers in PubMed.
- Prediction of acute kidney injury in mechanically ventilated patients with COVID-19-related septic shock: An exploratory analysis of non-renal organ dysfunction markers.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026Article
- Impact of infection on decongestion and kidney outcomes in patients with cardiorenal syndrome type 1.PloS one · 2026Article
- Jingui Shenqi pill ( ) treats cardiorenal syndrome by inhibiting mitogen-activated protein kinase signaling pathway and reducing inflammatory response.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Cardiorenal Syndrome: Molecular Pathways Linking Cardiovascular Dysfunction and Chronic Kidney Disease Progression.International journal of molecular sciences · 2025Review
- High-intensity interval training attenuates renal injury induced by myocardial ischemia-reperfusion in rats.Journal of the Chinese Medical Association : JCMA · 2025Article
- Improving Nutritional Status in Chronic Heart Failure Patients: Effectiveness of a Transtheoretical Model-Based Stepwise Nutritional Management Program.Risk management and healthcare policy · 2025Article
- Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists.Frontiers in medicine · 2024Review
- Metabolome Profiling in the Plasma of Dogs with Idiopathic Dilated Cardiomyopathy: A Multiplatform Mass-Spectrometry-Based Approach.International journal of molecular sciences · 2023Article
- Renal Biomarkers in Cardiovascular Patients with Acute Kidney Injury: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
- Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.Current heart failure reports · 2022Review
- The Impact of a New Arterial Intravascular Pump on Aorta Hemodynamic Surrounding: A Numerical Study.Bioengineering (Basel, Switzerland) · 2022Article
- Mechanism of PDZK1 in Hepatocellular Carcinoma Complicated with Hyperuricemia.Journal of oncology · 2022Article
- How to interpret serum creatinine increases during decongestion.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cardiorenal syndrome is a complex entity in which a primary heart dysfunction causes kidney injury (Types 1 and 2) and vice versa (Types 3 and 4), being either acute or chronic events, or maybe the result of a systemic disease that involves both organs (Type 5). Approximately 49% of heart failure cases present some grade of kidney dysfunction, significantly increasing morbidity and mortality rates. Its pathogenesis involves a variety of hemodynamic, hormonal and immunological factors that in the majority of cases produce fluid overload; the diagnosis and treatment of such constitutes the disease’s management basis. Currently, a clinical based diagnosis is insufficient and the use of biochemical markers, such as natriuretic peptides, or lung and heart ultrasound is required. These tools, along with urinary sodium levels, allow the evaluation of therapy effectiveness. The preferred initial decongestive strategy is based on a continuous infusion of a loop diuretic with a step-up dosing regimen, aiming for a minimal daily urine volume of 3 liters, with the possibility to sequentially add potassium sparing diuretics, thiazide diuretics and carbonic anhydrase inhibitors to reach the diuresis goal, leaving ultrafiltration as a last resource due to its higher rate of complications. Finally, evidence-based therapy should be given to improve quality of life, decrease mortality, and delay the deterioration of kidney and heart function over the long term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.